HEADER OXIDOREDUCTASE 05-APR-01 1IDT TITLE STRUCTURAL STUDIES ON A PRODRUG-ACTIVATING SYSTEM-CB1954 AND FMN- TITLE 2 DEPENDENT NITROREDUCTASE COMPND MOL_ID: 1; COMPND 2 MOLECULE: MINOR FMN-DEPENDENT NITROREDUCTASE; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: OXYGEN-INSENSITIVE NAD(P)H NITROREDUCTASE, DIHYDROPTERIDINE COMPND 5 REDUCTASE; COMPND 6 EC: 1.6.99.7; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: ESCHERICHIA COLI; SOURCE 3 ORGANISM_TAXID: 562; SOURCE 4 GENE: NFNB OR NFSI OR NFSB OR NTR OR DPRA OR B0578; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI B; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 37762; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: B KEYWDS FMN, BIOREDUCTIVE ACTIVATION, PRODRUG, OXIDOREDUCTASE EXPDTA X-RAY DIFFRACTION AUTHOR E.JOHANSSON,G.N.PARKINSON,W.A.DENNY,S.NEIDLE REVDAT 5 09-AUG-23 1IDT 1 REMARK HETSYN REVDAT 4 12-DEC-18 1IDT 1 HETSYN REVDAT 3 04-OCT-17 1IDT 1 REMARK REVDAT 2 24-FEB-09 1IDT 1 VERSN REVDAT 1 16-SEP-03 1IDT 0 JRNL AUTH E.JOHANSSON,G.N.PARKINSON,W.A.DENNY,S.NEIDLE JRNL TITL STUDIES ON THE NITROREDUCTASE PRODRUG-ACTIVATING SYSTEM. JRNL TITL 2 CRYSTAL STRUCTURES OF COMPLEXES WITH THE INHIBITOR JRNL TITL 3 DICOUMAROL AND DINITROBENZAMIDE PRODRUGS AND OF THE ENZYME JRNL TITL 4 ACTIVE FORM. JRNL REF J.MED.CHEM. V. 46 4009 2003 JRNL REFN ISSN 0022-2623 JRNL PMID 12954054 JRNL DOI 10.1021/JM030843B REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 31245 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.225 REMARK 3 FREE R VALUE : 0.269 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 2814 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.00 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.01 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2548 REMARK 3 BIN FREE R VALUE : 0.3004 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 51 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3362 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 98 REMARK 3 SOLVENT ATOMS : 192 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 29.28 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.006 REMARK 3 BOND ANGLES (DEGREES) : NULL REMARK 3 DIHEDRAL ANGLES (DEGREES) : 22.09 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.160 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1IDT COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 06-APR-01. REMARK 100 THE DEPOSITION ID IS D_1000013187. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 03-NOV-00 REMARK 200 TEMPERATURE (KELVIN) : 97 REMARK 200 PH : 4.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : BM14 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.976262 REMARK 200 MONOCHROMATOR : GERMANIUM 220 REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MAR REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 28476 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 90.3 REMARK 200 DATA REDUNDANCY : 13.14 REMARK 200 R MERGE (I) : 0.06400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 29.7600 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.07 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.7 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.20100 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: PDB ENTRY 1DS7 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.55 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.30 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PEG 4000, SODIUM ACETATE , PH 4.6, REMARK 280 VAPOR DIFFUSION, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 41 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z+1/2 REMARK 290 3555 -Y+1/2,X+1/2,Z+1/4 REMARK 290 4555 Y+1/2,-X+1/2,Z+3/4 REMARK 290 5555 -X+1/2,Y+1/2,-Z+1/4 REMARK 290 6555 X+1/2,-Y+1/2,-Z+3/4 REMARK 290 7555 Y,X,-Z REMARK 290 8555 -Y,-X,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 133.06450 REMARK 290 SMTRY1 3 0.000000 -1.000000 0.000000 28.77800 REMARK 290 SMTRY2 3 1.000000 0.000000 0.000000 28.77800 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 66.53225 REMARK 290 SMTRY1 4 0.000000 1.000000 0.000000 28.77800 REMARK 290 SMTRY2 4 -1.000000 0.000000 0.000000 28.77800 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 199.59675 REMARK 290 SMTRY1 5 -1.000000 0.000000 0.000000 28.77800 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 28.77800 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 66.53225 REMARK 290 SMTRY1 6 1.000000 0.000000 0.000000 28.77800 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 28.77800 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 199.59675 REMARK 290 SMTRY1 7 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY2 7 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 8 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY2 8 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 133.06450 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 9950 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 16700 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -41.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET B 1 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 41 18.08 54.81 REMARK 500 ALA A 64 46.02 -92.47 REMARK 500 THR B 41 16.57 59.04 REMARK 500 ASP B 198 107.82 -56.30 REMARK 500 REMARK 500 REMARK: NULL REMARK 600 REMARK 600 HETEROGEN REMARK 600 FMN 1218 AND CB1 1219 ARE ASSOCIATED WITH CHAIN A. REMARK 600 FMN 2218 AND CB1 2219 ARE ASSOCIATED WITH CHAIN B. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE FMN A 1218 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE FMN B 2218 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CB1 A 1219 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CB1 A 2219 DBREF 1IDT A 1 217 UNP P38489 NFNB_ECOLI 1 217 DBREF 1IDT B 1 217 UNP P38489 NFNB_ECOLI 1 217 SEQRES 1 A 217 MET ASP ILE ILE SER VAL ALA LEU LYS ARG HIS SER THR SEQRES 2 A 217 LYS ALA PHE ASP ALA SER LYS LYS LEU THR PRO GLU GLN SEQRES 3 A 217 ALA GLU GLN ILE LYS THR LEU LEU GLN TYR SER PRO SER SEQRES 4 A 217 SER THR ASN SER GLN PRO TRP HIS PHE ILE VAL ALA SER SEQRES 5 A 217 THR GLU GLU GLY LYS ALA ARG VAL ALA LYS SER ALA ALA SEQRES 6 A 217 GLY ASN TYR VAL PHE ASN GLU ARG LYS MET LEU ASP ALA SEQRES 7 A 217 SER HIS VAL VAL VAL PHE CYS ALA LYS THR ALA MET ASP SEQRES 8 A 217 ASP VAL TRP LEU LYS LEU VAL VAL ASP GLN GLU ASP ALA SEQRES 9 A 217 ASP GLY ARG PHE ALA THR PRO GLU ALA LYS ALA ALA ASN SEQRES 10 A 217 ASP LYS GLY ARG LYS PHE PHE ALA ASP MET HIS ARG LYS SEQRES 11 A 217 ASP LEU HIS ASP ASP ALA GLU TRP MET ALA LYS GLN VAL SEQRES 12 A 217 TYR LEU ASN VAL GLY ASN PHE LEU LEU GLY VAL ALA ALA SEQRES 13 A 217 LEU GLY LEU ASP ALA VAL PRO ILE GLU GLY PHE ASP ALA SEQRES 14 A 217 ALA ILE LEU ASP ALA GLU PHE GLY LEU LYS GLU LYS GLY SEQRES 15 A 217 TYR THR SER LEU VAL VAL VAL PRO VAL GLY HIS HIS SER SEQRES 16 A 217 VAL GLU ASP PHE ASN ALA THR LEU PRO LYS SER ARG LEU SEQRES 17 A 217 PRO GLN ASN ILE THR LEU THR GLU VAL SEQRES 1 B 217 MET ASP ILE ILE SER VAL ALA LEU LYS ARG HIS SER THR SEQRES 2 B 217 LYS ALA PHE ASP ALA SER LYS LYS LEU THR PRO GLU GLN SEQRES 3 B 217 ALA GLU GLN ILE LYS THR LEU LEU GLN TYR SER PRO SER SEQRES 4 B 217 SER THR ASN SER GLN PRO TRP HIS PHE ILE VAL ALA SER SEQRES 5 B 217 THR GLU GLU GLY LYS ALA ARG VAL ALA LYS SER ALA ALA SEQRES 6 B 217 GLY ASN TYR VAL PHE ASN GLU ARG LYS MET LEU ASP ALA SEQRES 7 B 217 SER HIS VAL VAL VAL PHE CYS ALA LYS THR ALA MET ASP SEQRES 8 B 217 ASP VAL TRP LEU LYS LEU VAL VAL ASP GLN GLU ASP ALA SEQRES 9 B 217 ASP GLY ARG PHE ALA THR PRO GLU ALA LYS ALA ALA ASN SEQRES 10 B 217 ASP LYS GLY ARG LYS PHE PHE ALA ASP MET HIS ARG LYS SEQRES 11 B 217 ASP LEU HIS ASP ASP ALA GLU TRP MET ALA LYS GLN VAL SEQRES 12 B 217 TYR LEU ASN VAL GLY ASN PHE LEU LEU GLY VAL ALA ALA SEQRES 13 B 217 LEU GLY LEU ASP ALA VAL PRO ILE GLU GLY PHE ASP ALA SEQRES 14 B 217 ALA ILE LEU ASP ALA GLU PHE GLY LEU LYS GLU LYS GLY SEQRES 15 B 217 TYR THR SER LEU VAL VAL VAL PRO VAL GLY HIS HIS SER SEQRES 16 B 217 VAL GLU ASP PHE ASN ALA THR LEU PRO LYS SER ARG LEU SEQRES 17 B 217 PRO GLN ASN ILE THR LEU THR GLU VAL HET FMN A1218 31 HET CB1 A1219 18 HET CB1 A2219 18 HET FMN B2218 31 HETNAM FMN FLAVIN MONONUCLEOTIDE HETNAM CB1 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE HETSYN FMN RIBOFLAVIN MONOPHOSPHATE HETSYN CB1 CB1954; TRETAZICAR FORMUL 3 FMN 2(C17 H21 N4 O9 P) FORMUL 4 CB1 2(C9 H8 N4 O5) FORMUL 7 HOH *192(H2 O) HELIX 1 1 ASP A 2 ARG A 10 1 9 HELIX 2 2 THR A 23 SER A 37 1 15 HELIX 3 3 SER A 39 SER A 43 5 5 HELIX 4 4 THR A 53 ALA A 61 1 9 HELIX 5 5 LYS A 62 ALA A 64 5 3 HELIX 6 6 ALA A 65 PHE A 70 5 6 HELIX 7 7 ASN A 71 ALA A 78 1 8 HELIX 8 8 ASP A 91 ASP A 105 1 15 HELIX 9 9 THR A 110 LYS A 130 1 21 HELIX 10 10 ASP A 134 LEU A 157 1 24 HELIX 11 11 ASP A 168 PHE A 176 1 9 HELIX 12 12 GLY A 177 GLY A 182 1 6 HELIX 13 13 ASP A 198 THR A 202 5 5 HELIX 14 14 PRO A 209 THR A 213 1 5 HELIX 15 15 ASP B 2 ARG B 10 1 9 HELIX 16 16 THR B 23 SER B 37 1 15 HELIX 17 17 SER B 39 SER B 43 5 5 HELIX 18 18 THR B 53 LYS B 62 1 10 HELIX 19 19 SER B 63 ALA B 65 5 3 HELIX 20 20 TYR B 68 PHE B 70 5 3 HELIX 21 21 ASN B 71 ALA B 78 1 8 HELIX 22 22 ASP B 91 ASP B 105 1 15 HELIX 23 23 THR B 110 ASP B 131 1 22 HELIX 24 24 ASP B 134 LEU B 157 1 24 HELIX 25 25 ASP B 168 PHE B 176 1 9 HELIX 26 26 GLY B 177 GLY B 182 1 6 HELIX 27 27 PRO B 209 THR B 213 1 5 SHEET 1 A 5 ASP A 160 ALA A 161 0 SHEET 2 A 5 TYR A 183 GLY A 192 -1 O GLY A 192 N ASP A 160 SHEET 3 A 5 HIS A 80 LYS A 87 -1 O HIS A 80 N VAL A 191 SHEET 4 A 5 TRP A 46 ALA A 51 -1 O HIS A 47 N CYS A 85 SHEET 5 A 5 LEU B 214 VAL B 217 1 N THR B 215 O PHE A 48 SHEET 1 B 5 LEU A 214 VAL A 217 0 SHEET 2 B 5 TRP B 46 ALA B 51 1 O PHE B 48 N THR A 215 SHEET 3 B 5 HIS B 80 LYS B 87 -1 O VAL B 81 N ALA B 51 SHEET 4 B 5 TYR B 183 GLY B 192 -1 O THR B 184 N ALA B 86 SHEET 5 B 5 ASP B 160 ALA B 161 -1 N ASP B 160 O GLY B 192 SITE 1 AC1 25 ARG A 10 HIS A 11 SER A 12 LYS A 14 SITE 2 AC1 25 PHE A 70 ASN A 71 LYS A 74 TYR A 144 SITE 3 AC1 25 PRO A 163 ILE A 164 GLU A 165 GLY A 166 SITE 4 AC1 25 ASN A 200 LYS A 205 ARG A 207 CB1 A2219 SITE 5 AC1 25 HOH A2223 HOH A2227 HOH A2249 PRO B 38 SITE 6 AC1 25 SER B 39 SER B 40 ASN B 42 GLN B 142 SITE 7 AC1 25 LEU B 145 SITE 1 AC2 21 PRO A 38 SER A 39 SER A 40 THR A 41 SITE 2 AC2 21 ASN A 42 GLN A 142 LEU A 145 CB1 A1219 SITE 3 AC2 21 ARG B 10 HIS B 11 SER B 12 LYS B 14 SITE 4 AC2 21 ASN B 71 TYR B 144 PRO B 163 ILE B 164 SITE 5 AC2 21 GLU B 165 GLY B 166 LYS B 205 ARG B 207 SITE 6 AC2 21 HOH B2290 SITE 1 AC3 6 THR A 41 PHE A 124 HOH A2291 PHE B 70 SITE 2 AC3 6 FMN B2218 HOH B2290 SITE 1 AC4 7 LYS A 14 PHE A 70 FMN A1218 HOH A2309 SITE 2 AC4 7 THR B 41 PHE B 124 HOH B2256 CRYST1 57.556 57.556 266.129 90.00 90.00 90.00 P 41 21 2 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017374 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017374 0.000000 0.00000 SCALE3 0.000000 0.000000 0.003758 0.00000